News from index pharmaceuticals A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

07 May, 2020, 07:17 BST InDex Pharmaceuticals Holding AB (publ) Interim Report January - March 2020

FDA and EMA endorse the advancement of cobitolimod into phase III studies "The positive responses from the regulators is an important external...


20 Apr, 2020, 18:32 BST Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)

The annual general meeting in InDex Pharmaceuticals Holding AB (publ) was held on Monday 20 April 2020 at Setterwalls Advokatbyrå's offices at...


16 Apr, 2020, 12:43 BST InDex Pharmaceuticals Advances Cobitolimod Further Towards Phase III Following Successful Interactions With FDA and EMA

InDex Pharmaceuticals Holding AB (publ) today announced that the company has received positive responses from FDA and EMA regarding phase III...


31 Mar, 2020, 07:15 BST InDex Pharmaceuticals Receives Grant From Vinnova for Pre-clinical Development of DIMS Compounds in Inflammation

InDex Pharmaceuticals Holding AB (publ) today announced that SEK 2.0 million has been granted from Sweden's innovation agency Vinnova to develop new, ...


25 Feb, 2020, 07:17 GMT InDex Pharmaceuticals Publishes Mechanism of Action Data for Cobitolimod in Scientific Journal

InDex Pharmaceuticals Holding AB (publ) today announced the publication of scientific data on the mechanism of action of cobitolimod, the company's...


20 Feb, 2020, 07:46 GMT InDex Pharmaceuticals Holding AB (publ) Year-end Report 2019

"The robustness and consistency of the CONDUCT results support our strategy to move cobitolimod forward in development and our phase III preparations ...


19 Feb, 2020, 20:11 GMT InDex Pharmaceuticals' In-depth Analysis of the CONDUCT Study Confirms the Successful Top Line Results and Supports the Strategy Going Forward

InDex Pharmaceuticals Holding AB (publ) today announced the conclusions from in-depth analysis of the complete data set from the phase IIb dose...


27 Nov, 2019, 07:18 GMT InDex Pharmaceuticals Holding AB (publ) Interim Report January - September 2019

"Something that really differentiates cobitolimod from its competitors is the superior safety profile. Both the approved drugs and those currently...


18 Nov, 2019, 07:23 GMT InDex Pharmaceuticals Presents at Redeye Life Science Day and Avanza Börsdag November 19, 2019

InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at ROOTS@Downtown ...


09 Oct, 2019, 17:16 BST Bulletin from Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ)

An Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) ("InDex" or the "Company") took place on Wednesday, October 9, 2019 in...


05 Sep, 2019, 08:10 BST InDex Pharmaceuticals Updates Shareholders List

InDex Pharmaceuticals Holding AB (publ) today announced that the list of shareholders has been updated on the homepage with information as of August...


27 Aug, 2019, 06:20 BST InDex Pharmaceuticals Meets Primary Endpoint in the Phase IIb Study CONDUCT with Cobitolimod in Ulcerative Colitis

InDex Pharmaceuticals Holding AB (publ) today announced positive top line results from the dose optimisation study CONDUCT, which is evaluating...


26 Jun, 2019, 15:06 BST InDex Pharmaceuticals Gets New Patent in Europe

InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the...


26 Jun, 2019, 08:51 BST InDex Pharmaceuticals Enrolls Last Patient in Phase IIb Study CONDUCT With Cobitolimod

InDex Pharmaceuticals Holding AB (publ) today announced that patient enrolment was completed in the dose optimisation study CONDUCT, which is...


11 Apr, 2019, 19:12 BST InDex Pharmaceuticals Provides Status Update on the Patient Recruitment in the CONDUCT Study

InDex Pharmaceuticals Holding AB (publ) today announced that 197 patients, of the total 215 planned, have been enrolled to date in the CONDUCT study...


20 Feb, 2019, 07:17 GMT InDex Pharmaceuticals Holding AB (publ) Year end Report 2018

STOCKHOLM, Feb. 20, 2019 /PRNewswire/ - Period October – December 2018 Revenues amounted to SEK 0.6 (0.0) million Operating result amounted to SEK...


19 Nov, 2018, 07:23 GMT InDex Pharmaceuticals Holding AB (publ) Interim Report January - September 2018

Period July – September 2018 Revenues amounted to SEK 0.0 (0.0) million Operating result amounted to SEK –15.1 (–13.3) million Result after tax...


23 Oct, 2018, 21:25 BST InDex Pharmaceuticals Carries Out a Directed Share Issue of Approximately SEK 37.5 Million

The board of directors of InDex Pharmaceuticals Holding AB (publ) (the "Company" or "InDex") has, with support from the authorization granted by the...


19 Oct, 2018, 07:38 BST InDex Pharmaceuticals Publishes Post-hoc Analysis of the COLLECT Study

InDex Pharmaceuticals Holding AB (publ) today announced the publication of a post-hoc analysis of COLLECT study data. COLLECT was a clinical study of ...


09 Aug, 2018, 19:54 BST InDex Pharmaceuticals Updates Timeline for Top Line Results from the CONDUCT Study to First Half of 2019

InDex Pharmaceuticals Holding AB (publ) today announced an updated timeline for patient recruitment in the ongoing phase IIb study CONDUCT with the...


31 May, 2018, 07:56 BST InDex Pharmaceuticals Will Participate in the Digestive Disease Week (DDW)

InDex Pharmaceuticals Holding AB (publ) today announced that the company will present two posters at the Digestive Disease Week (DDW). DDW is the...


04 May, 2018, 07:26 BST InDex Pharmaceuticals Develops Oral Formulation of Cobitolimod

InDex Pharmaceuticals Holding AB (publ) today announced that it has developed a novel formulation of its lead drug candidate cobitolimod for oral...


12 Apr, 2018, 10:58 BST InDex Pharmaceuticals Announces the Agenda for its Capital Markets Day in Stockholm on April 25, 2018

InDex Pharmaceuticals Holding AB (publ) ("InDex") today announced the agenda for its Capital Markets Day that will take place in Stockholm on...


28 Mar, 2018, 14:18 BST InDex Pharmaceuticals gets New Patent in Japan

InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod will be issued by the...


26 Feb, 2018, 07:49 GMT InDex Pharmaceuticals Holding AB (publ) Year end Report 2017

eriod October – December 2017 Revenues amounted to SEK 0.0 (0.3) million Operating result amounted to SEK –22.6 (–16.4) million Result after tax...